Plant Biotechnology Reports Biotechnology

From biosynthetic pathway architecture to quality prediction and biomanufacturing in east Asian medicinal plants: an architecture-centered perspective

Yu, Yingying, Liu, Junlong, Liu, Guosheng, Tang, Shengyao, Zhao, Jinchen, Zhou, Yuwei, Shi, Tian
Springer Nature · 2026-10-05 · DOI 10.1007/s11816-026-01084-1

Abstract

East Asian medicinal plants produce structurally diverse bioactive compounds through biosynthetic pathways whose genomic architectures vary substantially across species. Most reviews, however, are organized around species or omics technologies rather than pathway architecture, leaving a gap between correlative evidence and causal understanding. Here we argue that pathway architecture — whether core-cluster-associated, dispersed but cell-type-specialized, or driven by multi-branch competition and terminal glycosylation — shapes how pathway genes are discovered, how reliably chemotype can be predicted, and how readily a pathway can be reconstructed in heterologous hosts. We review genomic resources for pathway elucidation and introduce an evidence hierarchy distinguishing candidate discovery, functional validation, and in-planta causal evidence, thereby clarifying which claims rest on correlation rather than causation. Comparing the tanshinone, artemisinin, and ginsenoside pathways as contrasting architectural models, and examining the genotype–chemotype–environment evidence in Salvia miltiorrhiza , we identify where quality prediction is supported and where it breaks down. We close with three testable hypotheses, framing an architecture-centered perspective that prioritizes causal-validation experiments and anticipates engineering bottlenecks in biomanufacturing.

Read at publisher →